Skip to content

Extensively Hydrolyzed Formula: Hypoallergenicity

Evaluation of Hypoallergenicity of a 100% Whey, Extensively Hydrolyzed Infant Formula

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01278446
Enrollment
Unknown
Registered
2011-01-17
Start date
2011-02-28
Completion date
2012-08-31
Last updated
2013-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Food Hypersensitivity

Keywords

Cow's Milk Allergy, CMA

Brief summary

The primary objective of this clinical trial is to determine whether a new extensively hydrolyzed infant formula is hypoallergenic.

Interventions

OTHERExtensively hydrolyzed, whey protein infant formula

New hydrolyzed formula

OTHERExtensively hydrolyzed, casein protein infant formula

Commercially available hydrolyzed infant formula

Sponsors

Société des Produits Nestlé (SPN)
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
2 Months to 12 Years
Healthy volunteers
No

Inclusion criteria

1. Born at term (\>36 weeks gestation) 2. Two (2) months to ≤ 12 years of age at enrollment 3. Documented Cow's Milk Allergy (CMA) within the 6 months prior to enrollment by: 1. Reported convincing allergic symptoms following an exposure to milk or a milk-containing food product and \[detectable serum milk-specific IgE (\>0.7 kIU/L) or positive skin prick test (wheal greater than 5 mm\]), OR 2. Physician-supervised oral food challenge that elicited immediate allergic symptoms, OR 3. Results of laboratory tests highly predictive of clinical reactivity to milk * Serum milk IgE ≥15 \[kIU/L\]or ≥ 5 \[kIU/L if younger than 1 year OR, * Skin prick tests mean wheal \>10 mm 4. Otherwise healthy 5. If subject has asthma, atopic dermatitis, and/or rhinitis, must be well controlled 6. Expected daily intake of at least 8 oz (240 ml) of the study formula during the open challenge phase 7. Having obtained his/her legal representative's informed consent.

Exclusion criteria

1. Children consuming mother's milk at the time of inclusion and during the trial 2. Any chromosomal or major congenital anomalies 3. Any major gastrointestinal disease or abnormalities other than CMA 4. Chronic medical diseases (ie seizure disorders, chronic lung disease, heart problems (heart murmurs acceptable) 5. Immunodeficiency 6. Receiving free amino acid formula 7. Anti-histamine use in 7 days prior to the first food challenge (eyedrops are acceptable) 8. Oral steroid use within 14 days prior to enrollment (intranasal and topical corticosteroids are okay) 9. Unstable asthma 10. Severe uncontrolled eczema 11. Recent ( within the last 3 months) severe anaphylactic reaction to milk 12. Subject who in the Investigator's assessment cannot be expected to adhere to the study protocol 13. Currently participating in another clinical trial

Design outcomes

Primary

MeasureTime frameDescription
Hypoallergenicity14 DaysTo demonstrate that the test formula does not provoke allergenic activity

Secondary

MeasureTime frame
Digestive Tolerance1 Week

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026